Application of composition in medical products or drug manufacture for prevention and treatment of leukopenia caused by radiation and chemotherapy

FIELD: pharmacology.

SUBSTANCE: invention relates to application of a composition made from raw materials consisting of Radix Panacis Quinquefolii Ganoderma, or Radix Et Rhizoma Ginseng and fermented Cordyceps synesis powder and/or from Cordyceps, taken in a certain amount, in manufacture of medical products or drugs for prevention and treatment of radiation therapy or chemotherapy induced leukopenia in which the composition is obtained by raw materials mixing and extracting them with water and/or alcohol (versions).

EFFECT: compositions described above are effective in the manufacture of medical products or drugs for prevention and treatment of radiotherapy or chemotherapy-induced leukopenia.

25 cl, 36 tbl, 56 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of formula (I), possessing properties, making it possible to inhibit phosphorylation of AKT (proteinkinase B; PKB), to versions of method of their obtaining, as well as to intermediate products for their obtaining. In particular compounds can be applied in treatment of different tumours and/or metastases, as well as in case parasitic diseases such a malaria. In formula (I), R1 stands for -L-phenyl or -L-heteroaryl, with term "heteroaryl" standing for bicyclic radical, containing from 9 to 12 units, L stands for either linear or branched alkyl, containing 1-6 carbon atoms, optionally substituted with hydroxyl, or CO group, or group L'-X, where L' stands for linear or branched alkyl, containing 1-6 carbon atoms, and X stands for oxygen or sulphur atom; with phenyl and heteroaryl being optionally substituted with one or several radicals, similar or different, selected from halogen atoms, -NRxRy, alkoxy and alkyl; with said alkyl being optionally substituted with one or several halogen atoms; R2 stands for hydrogen atom or alkyl; R3 stands for alkyl, optionally substituted with one or several halogen atoms; R4 stands for hydrogen atom or halogen atom; with NRxRy being such that Rx and Ry form together with nitrogen atom, which they are bound to, cyclic radical, including 3-10 units, and optionally oxygen atom; and all alkyl or alkoxy radicals, mentioned above, are linear or branched and contain 1-6 carbon atoms.

EFFECT: compounds can be applied as active component for obtaining medications, intended for treatment or prevention of disease, characterised by deregulation of protein- or lipidkinase activity.

25 cl, 3 tbl, 43 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.

EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.

20 cl, 42 ex, 8 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to haematology, and can be used for hormonal and radiation preparation to the following radiation chemotherapy in the treatment of patients with chronic lymphocytic leukaemia. For this purpose prednisolone is introduced in a dose of 0.9-1.1 mg/kg of weight per day. Exposure to radiation in the doses and regimens, conventional for the treatment of lymphoid tumours of a low-degree of malignancy is also carried out in the term from 72 to 168 hours after the beginning of prednisolone introduction. After obtaining 2/3-3/4 of the total dose of the radiation impact, reduction of the dose of introduced prednisolone is realised with its cancellation by the end of the radiation impact. Exposed to radiation are: involved into the leukemic process lymphatic organs from the group: lymph nodes, tonsils, spleen and liver.

EFFECT: method ensures an increased efficiency of chemotherapeutical programmes due to the preliminary impact, making it possible to reduce the involvement of organs into the leukemic process, increased sensitivity of leukemic lymphocytes to the following chemotherapeutic impact , with the reduction of a probability of development of complications, for instance, such as febrile neutropenia.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula (I) X represents a C1-5-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; R1 represents a hydrogen atom or a C1-6-alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6-alkyl group, C2-6-alkenyl group, C3-6-cycloalkyl group, (C3-6-cycloalkyl)-C1-6-alkyl group, halogen-C1-6-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur/gimeracil/oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed.

EFFECT: preparing the intensifier of the antitumour effect.

18 cl, 10 dwg, 10 tbl, 67 ex

FIELD: medicine.

SUBSTANCE: invention can be used for treating recurrent acute myeloid leukaemia (AML) following the transplantation of allogenic haemopoietic stem cells. That is ensured by chemotherapy followed by administering (taking into account donor's leukocyte chimerism) donor's bone marrow lymphocytes in a combination with interleukin 2 (IL-2). The chemotherapy is conducted by the intravenous administration of anti-tumour preparations of cytabarine 100 mg/m2 twice a day for 7 days and indarubicine 12 mg/m2 1 time a day within 3 days. With underlying myelotoxic agranulocytosis with a granulocyte count of less than 0.5109/l, the donor's bone marrow lymphocytes are transfused is a dose of 1107 CD3+cells/kg of the patient's body weight that is followed by the intravenous drop-by-drop administration of IL-2 in a dose of 6 mln International Units 1-2 hours later. The 100% absence of the donor's leukocyte chimerism and any signs of the graft vs. host disease, the following two donor's lymphocyte transfusions and IL-2 infusions in a dose of 6 mln International Units are performed the first of the two donor's bone marrow lymphocyte transfusions is performed in a dose of 5107 CD3+cells/kg, and the second one - in a dose of 1108 CD3+cells/kg. The transfusion cycle makes 2-4 weeks. That is followed by therapeutic supporting course of IL-2 administration in a dose of 2 mln International Units a day for 5 days intravenously; the course cycle makes 4-5 weeks with the supporting therapy lasting for 2 years.

EFFECT: higher clinical effectiveness of post-transplantation recurrence, achieved long-lasting recurrent remissions, higher overall survival rate in the patients with acute myeloid leukaemia.

2 ex

FIELD: medicine.

SUBSTANCE: present invention refers to immunology. What is presented is using Blinatumomab (MT103) for preparing a pharmaceutical composition for treating, relieving or eliminating acute lymphoblastic leukaemia (ALL), wherein Blinatumomab (MT103) transforms a MRD (minimal residual disease) positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL.

EFFECT: using the invention provides transforming the MRD-positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL molecularly that can find application in medicine in the therapy of recurrent ALL.

21 cl, 8 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: present invention refers to immunology. What is presented is using Blinatumomab for producing a pharmaceutical composition for treating, relieving or eliminating acute lymphoblastic leukaemia(ALL) in children, wherein Blinatumomab transforms MRD (a minimal residual disease) - positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL.

EFFECT: using the invention provides transforming MRD-positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL at the molecular level that can find application in medicine in therapy of recurrent ALL in children.

23 cl, 5 dwg, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of general formula [1] or their pharmaceutically acceptable salts, which possess properties of an inhibitor of the JAK2 thyrokinase activity. In general formula radicals are selected from group (I) or (II). In group (I) X represents CH or N; R1 represents a halogen atom and R2 represents H, a halogen atom, CN, or is selected from the groups of formulas

,

or a group -ORP or 5-6-membered heteroaryl, containing 1-4 nitrogen atoms and optionally additionally containing an oxygen or sulphur atom or containing an oxygen atom as a heteroatom, optionally substituted; or (II) X represents -CRA; and RA represents a group of formula , RB represents (a) amino, optionally substituted with one or two groups, selected from the group, consisting of C1-6alkyl, C3-6cycloalkyl, (C3-6cycloalkyl)C1-6alkyl and C1-3alcoxyC1-3alkyl, (b) C1-3alcoxy, (c) hydroxy or (d) a 5-6-membered saturated cyclic amino group, which additionally can contain a heteroatom, selected from an oxygen atom; R1 represents a halogen atom and R2 represents H; R3 -R5 have values given above. Other values of the radicals are given in the invention formula.

EFFECT: compounds can be applied for the prevention or treatment of cancer, for instance hematologic cancer disease or a solid form of cancer, inflammatory disorder, for instance, rheumatoid arthritis, inflammatory intestinal disease, osteoporosis or multiple sclerosis and angiopathy, for instance, pulmonary hypertension, arteriosclerosis, aneurism or varicose veins.

14 cl, 19 tbl, 234 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to molecular biology, molecular genetics and biotechnology, and can be used in medicine, as well as in agriculture and industrial biotechnology for the development of a fundamentally new approach to antileukaemic therapy with the use of low-molecular compounds against specific molecular targets, which include molecules of subunits of voltage-gated potassium channels of the family Kv. What is presented is using potassium channel inhibitors specified in diltiazem hydrochloride, anandamide (arachidonylethanolamide), verapamil hydrochloride, linoleic acid as an agent for enhancing the apoptosis of tumour B-cells in chronic lymphatic leukaemia. The technical effect is achieved by the fact that the low-molecular compounds are used to simulate the inhibitory effect of the KCNRG protein, which inhibits the normal assembly of potassium channel proteins by binding to the region responsible for their tetramerisation and thereby suppressing the channel activity.

EFFECT: creating the potassium channel inhibitors used as an agent to induce the apoptosis of tumour B-cells in chronic lymphatic leukaemia.

2 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: perorally delivered pharmaceutical composition contains a compound, which inhibits a protein of family Bcl-2, in particular ABT-263, a slightly soluble in lipids antioxidant, selected from the group, which consists of sulphites, bisulphites, metabisulphites, thiosulphates and their mixtures, and an in fact non-aqueous lipid carrier, which includes a phospholipid, a non-phospholipid surface-active substance and a solubilising component, which includes one or more glycols, glycolides and/or glyceride compounds, where the said compound ABT-263 and the said antioxidant are in a solution in the lipid carrier.

EFFECT: composition is suitable for peroral introduction to an individual who requires it for treatment of a disease, characterised by superexpression of one or some antiapoptotic proteins of family Bcl-2, for example cancer.

28 cl, 2 dwg, 17 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: what is described is a microdispersed histo-equivalent bioplastic material containing hyaluronic acid, a buffer system, clarithromycin and a proton pump inhibitor. Hyaluronic acid is nanostructured, lyophilised and dispersed to powder with a single particle size falling within the range of 50-100 mcm; the buffer system is Buffer-G with pH 6.8-8.0, while the proton pump inhibitor is the inhibitor H+-K+-Adenosine triphosphatase pantoprazole in the following proportions, wt %: hyaluronic acid - 95, Buffer-G with pH 6.8-8.0- 3, pantoprazole -1, clarithromycin -1; the microdispersed histo-equivalent bioplastic material is placed into capsules melted on exposure to body temperature, e.g. gelatine.

EFFECT: using it for the therapeutic treatment of gastroduodenal ulcers and erosions with the effect of accelerated oral tissue regeneration.

1 tbl

FIELD: medicine.

SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.

EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.

10 cl, 4 ex, 3 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a pharmaceutical composition, namely to a method of manufacturing a solid, coated pharmaceutical composition by the method of applying a coating by melt.

EFFECT: method is adapted to the provision of the solid, coated pharmaceutical composition, possessing fast release, by means of covering by melt.

6 ex, 8 tbl, 13 cl

FIELD: medicine.

SUBSTANCE: invention represents an oral anti-enteroviral and immunostimulant agent in the form of capsules containing interferon and additives, differing by the fact that a therapeutic substance is human recombinant interferon alpha-2b immobilised on polyethylene glycol, having a molecular weight of 1.5 kD by a physical method of binding by an accelerated electron flow in a dose of 1.5 Mrad. The ingredients in the agent are taken in a certain ratio.

EFFECT: extending the range of anti-enteroviral agents possessing immunostimulant properties.

6 ex, 10 tbl

FIELD: medicine.

SUBSTANCE: presented egg-shaped vaginal suppositories contains the following mass ratio in 1 capsule (egg-shaped vaginal suppository): sulphadimine 0.05 g; metronidazole 0.01 g, potato starch 0.02 g, glucose 0.04 g, 5% polyvinyl alcohol 0.07 g, 15% oily extract of propolis 1.0 g; gelatine 0.2 g; dimethicone 0.04 g; glycerol 0.4 g; purified water 0.37 g.

EFFECT: using the invention increases the therapeutic effect and bioavailability of the capsules, increases the prolonged action time, provides the control release of the active substances.

3 cl, 1 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns a simplified capsular form of clofazimine, containing clofazimine, bee wax, soya bean lecithin, butylhydroxy toluene, soya bean oil, gelatine, glycerol, sorbitol, methylparabene, propylparabene, titanium dioxide, brown chocolate and purified water with preserving high efficacy.

EFFECT: simplifying the form.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention represents an encapsulated liposomal antiviral agent based on human interferon alpha-2b for vaginal application, characterised by the fact that each capsule is made in the form of a hollow coating, which encloses a powder excipient and liposomes distributed in the excipient, and sodium alginate, a water-soluble polymer gel former; the excipient consists of lactose, sodium chloride, 12-aqueous disodium hydrogen phosphate and sodium dihydrogen phosphate, whereas each of the liposomes represents a hollow coating containing lecithin, cholesterol and alpha-tocopherol, and a nucleus inside the coating and containing recombinant human interferon alpha-2; the ingredients of the agents are taken in a certain ratio, mg.

EFFECT: maintaining the storage activity of recombinant human interferon alpha-2 and prolonged action in vaginal application.

2 cl, 3 dwg, 6 tbl, 6 ex

Abt-263 capsule // 2550956

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics, in particular, described is a capsule, containing a capsule envelope, which includes an encapsulated liquid solution of N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)3-(morpholin-4-yl)-1-(phenylsulphanyl)methyl)propyl)-amino)-3-((trifluoromethyl)sulphonyl)benzenesulphonamide (ABT-263) or its bis-hydrochloride salts in a non-ethanol carrier. As filling agents used are: a phospholipid, a solubilising agent for the phospholipid, selected from glycols, glycolides, glycerides and their mixtures, a surface-active substance of a non-phospholipid type and a sulphur-containing antioxidant in an amount, effective for the reduction of oxidising ABT-263 degradation in storage. The sulphur-containing antioxidant is selected from sulphites, bisulphites, metabisulphites and thiosulphites and their mixtures. A method of the capsule obtaining is also described. The capsule is used for treating a disease, characterised by the overexpression of one or several anti-apoptotic proteins of the Bcl-2 family, for instance, cancer.

EFFECT: invention provides a long storage term for the said capsule.

33 cl, 3 dwg, 20 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a formulation of a cough medical composition. The formulation of the cough medical composition contains an active substance presented by thermopsis herb powder or a dry extract of thermopsis and sodium hydrocarbonate, as well as an excipient, a granulating agent and a lubricant taken in certain relations (versions).

EFFECT: composition of the cough medical composition possesses improved pharmaceutical (appearance, taste) and technological characteristics (hardness, disintegration).

11 cl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a storage-stable pharmaceutical composition and a pharmaceutical formulation containing at least one active pharmaceutical ingredient presenting a nitrocatechol derivative, 2,5-dichlor-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide, at least one excipients and at least one binding agent, wherein at least one excipient is other than a phosphate derivative, wherein at least one binding ingredient is other than a polyvinylpyrrolidone compound, and wherein the above active pharmaceutical ingredient is present in the granulated form.

EFFECT: compositions and/or formulations according to the invention are stable for a long period of time and show a high stability if stored in the high temperature and moisture environment.

26 cl, 8 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to biodegradable water-insoluble polyethyleneglycol-based hydrogels. The claimed invention also deals with conjugates of such biodegradable hydrogels with affinity ligands or chelating groups or ion-exchange groups, bound with carriers of prodrugs, in which a biodegradable hydrogel in accordance with the claimed invention is the carrier, and their pharmaceutical compositions, as well as to their application as a drug. Described is a biodegradable water-insoluble poly(ethyleneglycol)-based hydrogel, containing fragments of the main chain, connected by hydrolytically degradable bonds, with fragments of the main chain being characterised by the molecular weight in the range from 1 kDa to 20 kDa and having the structure C*-(A-Hyp)x, where C* represents a branching core, A represents a polymer poly(ethyleneglycol)-based chain, Hyp represents a super-branched dendrite fragment, x represents an integer number from 3 to 15; and where the superbranched dendrite fragment additionally contains reactionable functional groups and connecting functional groups, with the fragments of the main chain being connected together by means of cross-linking fragments, and each cross-linking fragment has at least two hydrolytically degradable bonds at the end. A conjugate and a bound with the carrier prodrug, containing the said biodegradable hydrogel, and the application of the prodrug in a medication are also described. Also described are: a method of obtaining the said hydrogel, which includes a stage (a) reacting of a main chain reagent, and the hydrogel, obtained by the claimed method, in the form of a coating mesh, a stent or a microparticle, obtained by crashing by mechanical methods, such as mixing, breaking, cutting pressing or milling, and sieving in case of necessity.

EFFECT: disclosed are the methods of obtaining the prodrug, the method of obtaining the prodrug, injected through the needle, and the prodrug, obtained by the claimed method.

38 cl, 41 ex, 15 dwg

Up!